

Attorney Docket No.: 6259.200-US  
Larsen et al.  
Serial No.: 10/076,025

### REMARKS

Applicants are submitting this amendment in response to the Notice of Non-Compliant Amendment, mailed 8/25/2004 and respectfully request that the Examiner consider this amendment, in which the issue regarding claim numbering is addressed, in place of the previously filed April 23, 2004 amendment.

Accordingly, claims 1-15 have been canceled without prejudice or disclaimer. The new claims presented contain the subject matter that the Examiner deemed allowable in the last office action and address any 112 rejections and objections. In particular, claims 28-30 track old claims 6-9.

It is respectfully submitted that the present amendment presents no new issues or new matter and places this case in condition for allowance. Reconsideration of the application in view of the above amendments and the following remarks is requested.

Attorney Docket No.: 6259.200-US  
Larsen et al.  
Serial No.: 10/076,025

### Conclusion

In view of the above, it is respectfully submitted that all claims are in condition for allowance. Early action to that end is respectfully requested. The Commissioner is hereby authorized to charge any fees in connection with this application and to credit any overpayments to Deposit Account No. 14-1447. The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,

Date: September 9, 2004



Marc A. Began, Reg. No. 48,829  
Novo Nordisk Pharmaceuticals, Inc.  
100 College Road West  
Princeton, NJ 08540  
(609) 987-5800

Use the following customer number for all correspondence regarding this application.

**23650**

PATENT TRADEMARK OFFICE